
The FY2027 appropriations process gives Congress an immediate opportunity to protect medical cannabis patients from discrimination while addressing the gaps left by the Attorney General's order. Through funding directives, legislative provisions, and committee report language, Congress can require federal agencies to protect patients, update outdated policies, and establish the safeguards necessary for safe access and healthcare integration. These actions cannot replace comprehensive medical cannabis legislation, but they can help ensure that patients are not left behind while Congress develops a national framework.
For ASA's complete appropriations agenda, detailed requests across all seven subcommittees, and the latest congressional developments, visit our FY2027 Medical Cannabis Appropriations Hub. The hub will be updated as Congress considers FY2027 funding legislation and patient advocacy opportunities.
DOWNLOAD PROPOSED AG APPROPS LANGUAGE | TAKE ACTION
WHY THIS SUBCOMMITTEE SHOULD ACT
The Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee is directly responsible for addressing gaps in federal cannabinoid product oversight because its appropriations legislation funds the Food and Drug Administration (FDA) and served as the vehicle Congress used to revise the federal definition of hemp in FY2026. Those changes restrict which hemp-derived cannabinoid products qualify as hemp under federal law, but they do not establish the comprehensive testing, labeling, safety disclosure, and quality standards that patients and consumers need.
The widespread availability of hemp-derived cannabinoid products has created a false sense of security about their safety and federal oversight. Patients and consumers may assume that products sold online or in retail stores have been evaluated for safety, accurately labeled, or tested for contaminants, even when those safeguards have not been verified. In 2023, FDA acknowledged that existing food and dietary supplement regulatory pathways were inadequate for CBD products and that a new regulatory pathway was needed. Congress has yet to establish that framework, leaving significant gaps in oversight for products that remain eligible for lawful marketing.
Congress can address these gaps by giving FDA authority to set basic labeling and safety disclosure requirements while directing the agency to evaluate real-world medical cannabis evidence and develop product safety recommendations. These actions would improve consumer transparency, support consistent medical cannabis product standards, and provide a foundation for healthcare integration without replacing the need for comprehensive federal legislation.
ASA'S FY2027 APPROPRIATIONS REQUEST |
Americans for Safe Access requests that Congress direct FDA to establish federal labeling and safety disclosure requirements for hemp-derived cannabinoid products, including accurate cannabinoid information, product traceability, contaminant-testing disclosures, and clear statements concerning FDA evaluation or approval. Congress should provide the specific authority necessary to establish enforceable requirements while ensuring that these provisions do not alter the statutory definition of hemp or authorize products otherwise prohibited under federal law.
ASA also requests that FDA use its real-world evidence framework to evaluate existing medical cannabis research, state patient-program data, international evidence, and gaps in healthcare professional education. In coordination with HHS and other relevant agencies, FDA should develop medical cannabis and cannabinoid product safety recommendations covering testing, labeling, product consistency, stability, storage, and recalls. Together, these actions would strengthen patient safety and provide a foundation for national medical cannabis standards while Congress considers comprehensive legislation.
A. FDA HEMP-DERIVED CANNABINOID LABELING & SAFETY DISCLOSURE REQUIREMENTS |
The widespread availability of these products has created a false sense of security among patients and consumers about their safety. While the FDA cannot regulate these products without Congress creating a new pathway, it can ensure consumers understand the lack of regulation and oversight. Direct the FDA to issue protocols requiring manufacturers of CBD and other hemp-derived cannabinoid products to comply with basic federal labeling and safety disclosure requirements.
Purpose: Patients and consumers need transparent labeling, batch identification, and contaminant-testing information, especially while federal cannabinoid policy remains fragmented.
PROPOSED BILL LANGUAGE:
SEC. __. HEMP-DERIVED CANNABINOID LABELING AND SAFETY DISCLOSURES.
(a) Not later than 30 days after the date of enactment of this Act, the Commissioner of Food and Drugs shall issue guidance describing minimum labeling and safety disclosure standards for consumer products represented as containing cannabidiol or other hemp-derived cannabinoids.
(b) The Commissioner is authorized and directed to establish enforceable labeling and safety disclosure requirements for covered hemp-derived cannabinoid products, including:
(1) Identification of the cannabinoid source and manufacturer or responsible distributor.
(2) Identification of the cannabinoids present and their labeled quantities, including applicable THC content.
(3) A clear statement indicating whether the product has been approved by the Food and Drug Administration and, where applicable, that FDA has not evaluated the product for safety or effectiveness.
(4) Disclosure of available contaminant and adulterant testing information, including a certificate of analysis or a readily accessible QR code or electronic link to product-specific testing results.
(5) A lot or batch number sufficient to support product identification, traceability, and recall procedures.
(6) Information necessary to report product quality concerns or adverse events.
(c) Not later than 180 days after enactment, the Commissioner shall promulgate implementing regulations establishing the format, accessibility, and minimum verification requirements for the disclosures specified in subsection (b).
(d) Nothing in this section shall be construed to amend the federal definition of hemp under section 297A of the Agricultural Marketing Act of 1946, authorize the marketing of a product otherwise prohibited by federal law, confer FDA approval on an unapproved product, or exempt a manufacturer or distributor from other applicable federal or state requirements.
PROPOSED COMMITTEE REPORT LANGUAGE
Hemp-Derived Cannabinoid Product Transparency and Consumer Safety.
The Committee recognizes that recent statutory changes to the federal definition of hemp restrict the availability of certain cannabinoid products but do not establish comprehensive federal labeling, testing, or safety disclosure standards for products remaining in the marketplace. The Committee is concerned that patients and consumers may lack reliable information concerning cannabinoid content, product consistency, contamination risks, and the extent of FDA oversight.
The Committee directs FDA to develop minimum labeling and safety disclosure requirements for hemp-derived cannabinoid products, including accurate identification of cannabinoid content, product origin, batch information, contaminant-testing disclosures, and FDA approval status. The Committee expects FDA to work with state regulatory authorities and relevant public-health agencies to identify practical mechanisms for providing consumers with access to product-specific testing information.
The Committee further directs FDA to identify any additional statutory or regulatory authority needed to implement comprehensive cannabinoid product safety standards and report those needs to the Committees on Appropriations.

B. FDA REAL-WORLD EVIDENCE FRAMEWORK & MEDICAL CANNABIS REPORT |
State medical cannabis programs have generated substantial patient experience and observational data, but federal research has not systematically evaluated much of this information in connection with broader medical cannabis research, healthcare education, and future regulatory needs. At the same time, healthcare professionals continue to encounter patients who take medical cannabis products without consistent clinical documentation, reliable product information, or standardized educational resources.
Purpose: Federal agencies should learn from state medical cannabis programs, patient outcomes, accredited research centers, international studies, and existing healthcare education initiatives. A comprehensive assessment would identify research limitations, strengthen future study design, and help states harmonize information needed for healthcare integration.
PROPOSED BILL LANGUAGE
SEC. __. REAL-WORLD EVIDENCE REPORT ON MEDICAL CANNABIS.
Not later than one year after the date of enactment of this Act, the Commissioner of Food and Drugs, acting through the Center for Drug Evaluation and Research and, as appropriate, the Center for Biologics Evaluation and Research, and in consultation with the Secretary of Health and Human Services and other relevant federal agencies, shall submit a report to the Committees on Appropriations on medical cannabis research, real-world evidence, knowledge gaps, and healthcare professional education in the United States.
The Commissioner shall apply relevant principles of the FDA's real-world evidence framework to assess the availability, quality, limitations, and potential research applications of data concerning medical cannabis and cannabinoid products.
The report shall include:
(1) An overview of domestic and international medical cannabis research, including clinical studies, observational research, real-world evidence, and identified limitations in the available data.
(2) An assessment of the availability and quality of information generated through state-authorized medical cannabis programs, including patient characteristics, qualifying conditions, product characteristics, reported outcomes, adverse events, and other information relevant to research and patient safety.
(3) Identification of opportunities for federal agencies, state medical cannabis programs, accredited research institutions, and healthcare systems to improve research coordination and data collection.
(4) An assessment of medical cannabis and endocannabinoid system education in premedical, medical, graduate medical, continuing medical education, and other relevant healthcare professional training programs.
(5) An assessment of the effect of Accreditation Council for Continuing Medical Education standards and published guidance on the availability and content of accredited cannabis-related continuing medical education.
(6) Recommendations for state medical cannabis programs to harmonize data collection, including standardized terminology, product information, patient-reported outcomes, adverse-event documentation, and appropriate patient privacy protections.
(7) Identification of research, educational, data infrastructure, and regulatory gaps that must be addressed to support future medical cannabis healthcare integration.
The Commissioner shall distinguish evidence demonstrating clinical benefits or risks from preliminary observational findings and shall identify where additional controlled research is necessary.
PROPOSED COMMITTEE REPORT LANGUAGE
Medical Cannabis Real-World Evidence, Research, and Healthcare Education.
The Committee recognizes that state medical cannabis programs, domestic and international research institutions, and healthcare professionals have developed substantial information concerning medical cannabis and cannabinoid products. However, limitations in data quality, inconsistent reporting methods, and gaps in clinical education continue to limit federal agencies' ability to evaluate patient experiences and translate research findings into appropriate healthcare guidance.
The Committee directs FDA to undertake a comprehensive assessment of medical cannabis research and real-world evidence, including the information available from state-authorized medical cannabis programs and opportunities to improve data collection and coordination. The assessment should identify the extent to which existing data can inform future research, characterize risks and benefits, and support evidence-based decision-making while recognizing the limitations of observational evidence.
The Committee further directs FDA to assess medical cannabis and endocannabinoid system education across healthcare training programs and evaluate the effect of applicable accreditation standards and guidance on continuing medical education. The report should recommend practical steps to improve research collaboration, harmonize state data collection, protect patient privacy, and identify educational needs relevant to eventual healthcare integration.
C. MEDICAL CANNABIS AND CANNABINOID PRODUCT SAFETY STANDARDS |
Patients taking medical cannabis and cannabinoid products need reliable information about product identity, composition, consistency, contamination, and stability. State medical cannabis programs have developed differing approaches to testing, labeling, packaging, storage, and recalls, while federal guidance primarily addresses specific FDA-regulated products or the development of cannabis-derived drugs for clinical research. This leaves important opportunities for federal agencies to identify common safety priorities that can inform state programs and future national standards.
Direct FDA, in coordination with HHS and relevant federal agencies, to develop medical cannabis and cannabinoid product safety guidance and recommendations. The recommendations should address testing, labeling accuracy, contamination risks, cannabinoid content, product consistency, stability, storage, packaging, expiration dating, adverse-event reporting, and recall procedures.
Purpose: Consistent product safety standards would help patients, caregivers, healthcare professionals, researchers, and regulators evaluate the quality and reliability of medical cannabis and cannabinoid products. Federal recommendations could improve coordination among state programs while identifying the regulatory authorities and scientific work necessary for comprehensive national standards.
PROPOSED BILL LANGUAGE
SEC. __. MEDICAL CANNABIS AND CANNABINOID PRODUCT SAFETY.
(a) The Commissioner of Food and Drugs, in coordination with the Secretary of Health and Human Services and other relevant federal agencies, shall develop guidance or recommendations concerning product safety, quality, labeling, testing, stability, storage, and recall procedures for medical cannabis and cannabinoid products obtained by patients through state-authorized medical cannabis programs.
(b) The guidance or recommendations shall address:
(1) Cannabinoid identity, content, potency, and labeling accuracy.
(2) Testing for microbial contamination, pesticides, heavy metals, residual solvents, and other substances presenting potential health risks.
(3) Product consistency, batch identification, and traceability.
(4) Stability testing, appropriate storage conditions, shelf life, and expiration dating.
(5) Packaging and labeling considerations relevant to safe administration, product identification, and patient information.
(6) Adverse-event reporting, product quality complaints, safety alerts, and recall procedures.
(7) Appropriate testing methods, laboratory quality assurance, and opportunities for harmonizing state medical cannabis safety requirements.
(c) In developing the guidance or recommendations, the Commissioner shall consult state medical cannabis regulatory authorities, healthcare professionals, patient representatives, qualified testing laboratories, accredited research institutions, and relevant federal agencies.
(d) Not later than one year after enactment, the Commissioner shall submit to the Committees on Appropriations a report identifying recommended national medical cannabis product safety priorities, existing federal guidance and regulatory authorities, opportunities for coordination with state programs, and any additional statutory authority necessary to establish comprehensive and enforceable federal standards.
PROPOSED COMMITTEE REPORT LANGUAGE
Medical Cannabis and Cannabinoid Product Safety Standards.
The Committee recognizes that product quality and safety are essential considerations for patients who depend on medical cannabis and cannabinoid products. Variation among state testing, labeling, storage, and recall requirements can create inconsistencies in the information available to patients, healthcare professionals, researchers, and regulators.
The Committee directs FDA, in coordination with HHS and relevant federal agencies, to develop recommendations addressing cannabinoid content and labeling accuracy, contaminant testing, laboratory quality assurance, product stability, shelf life, packaging, storage, adverse-event reporting, and recall procedures. The Committee expects FDA to consider existing state medical cannabis standards, relevant international approaches, and established pharmaceutical and botanical product quality principles when identifying priorities that may be adapted to medical cannabis products.
The Committee further directs FDA to consult patient representatives, state regulators, clinicians, researchers, and qualified laboratories to identify practical opportunities for harmonizing safety standards. FDA shall report to the Committees on Appropriations within one year on recommended safety priorities, opportunities for federal and state coordination, and any additional authority required to establish comprehensive national standards
DOWNLOAD PROPOSED AG APPROPS LANGUAGE| TAKE ACTION
THE PATH FORWARD |
The priorities outlined here are part of Americans for Safe Access' coordinated FY2027 appropriations agenda across seven congressional subcommittees. Together, these requests seek to protect patients, remove discriminatory barriers, strengthen federal accountability, and establish the policies necessary to integrate medical cannabis into American healthcare.
Congress can take meaningful action through the appropriations process while laying the groundwork for comprehensive medical cannabis legislation in the 120th Congress. Patients should not have to choose between the medicine they rely on and their healthcare, housing, livelihoods, or fundamental rights. Explore ASA's complete FY2027 Medical Cannabis Appropriations Agenda to learn how these requests work together and follow the latest congressional developments.
References & Sources
|
Share this page